295 related articles for article (PubMed ID: 11306482)
1. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing.
Black ME; Kokoris MS; Sabo P
Cancer Res; 2001 Apr; 61(7):3022-6. PubMed ID: 11306482
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.
Kokoris MS; Sabo P; Adman ET; Black ME
Gene Ther; 1999 Aug; 6(8):1415-26. PubMed ID: 10467366
[TBL] [Abstract][Full Text] [Related]
4. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy.
Kokoris MS; Sabo P; Black ME
Anticancer Res; 2000; 20(2A):959-63. PubMed ID: 10810381
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of prodrugs ability to induce effective ablation of cells transduced with viral thymidine kinase gene.
Kuriyama S; Nakatani T; Masui K; Sakamoto T; Tominaga K; Yoshikawa M; Fukui H; Ikenaka K; Tsujii T
Anticancer Res; 1996; 16(5A):2623-8. PubMed ID: 8917361
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy.
Xie Y; Gilbert JD; Kim JH; Freytag SO
Clin Cancer Res; 1999 Dec; 5(12):4224-32. PubMed ID: 10632364
[TBL] [Abstract][Full Text] [Related]
8. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.
Kokoris MS; Black ME
Protein Sci; 2002 Sep; 11(9):2267-72. PubMed ID: 12192082
[TBL] [Abstract][Full Text] [Related]
9. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
10. Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene.
Kim JH; Kolozsvary A; Rogulski K; Khil MS; Brown SL; Freytag SO
Cancer J Sci Am; 1998; 4(6):364-9. PubMed ID: 9853135
[TBL] [Abstract][Full Text] [Related]
11. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
12. Resistance developing after long-term ganciclovir prodrug treatment in a preclinical model of NSCLC.
Kurdow R; Schniewind B; Boehle AS; Haye S; Boenicke L; Dohrmann P; Kalthoff H
Anticancer Res; 2004; 24(2B):827-31. PubMed ID: 15161034
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Wang HE; Yu HM; Liu RS; Lin M; Gelovani JG; Hwang JJ; Wei HJ; Deng WP
J Nucl Med; 2006 Jul; 47(7):1161-71. PubMed ID: 16818951
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells.
Shewach DS; Zerbe LK; Hughes TL; Roessler BJ; Breakefield XO; Davidson BL
Cancer Gene Ther; 1994 Jun; 1(2):107-12. PubMed ID: 7621241
[TBL] [Abstract][Full Text] [Related]
15. [Herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV(1)-TK/GCV) system as an effective "in vivo death switch" of live tumor vaccines].
Kang Y; Xu CJ; Liu XS; Wu CQ; Zhong CP; Gu JR
Ai Zheng; 2005 Aug; 24(8):909-14. PubMed ID: 16086864
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET.
Tseng JC; Zanzonico PB; Levin B; Finn R; Larson SM; Meruelo D
J Nucl Med; 2006 Jul; 47(7):1136-43. PubMed ID: 16818948
[TBL] [Abstract][Full Text] [Related]
17. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy.
Frank S; Steffens S; Fischer U; Tlolko A; Rainov NG; Kramm CM
Cancer Gene Ther; 2002 Feb; 9(2):178-88. PubMed ID: 11857036
[TBL] [Abstract][Full Text] [Related]
18. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
[TBL] [Abstract][Full Text] [Related]
19. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
Burrows FJ; Gore M; Smiley WR; Kanemitsu MY; Jolly DJ; Read SB; Nicholas T; Kruse CA
Cancer Gene Ther; 2002 Jan; 9(1):87-95. PubMed ID: 11916247
[TBL] [Abstract][Full Text] [Related]
20. Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing.
Rubsam LZ; Davidson BL; Shewach DS
Cancer Res; 1998 Sep; 58(17):3873-82. PubMed ID: 9731497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]